

Resource Summary Report

Generated by [dkNET](#) on Aug 19, 2026

InVivoMab anti-mouse IL-1 R (CD121a)

RRID:AB_2661843

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0256, RRID:AB_2661843)

Antibody Information

URL: http://antibodyregistry.org/AB_2661843

Proper Citation: (Bio X Cell Cat# BE0256, RRID:AB_2661843)

Target Antigen: IL-1 R (CD121a)

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: in vitro Neutralization & Blocking, in vivo Neutralization & Blocking

Antibody Name: InVivoMab anti-mouse IL-1 R (CD121a)

Description: This monoclonal targets IL-1 R (CD121a)

Target Organism: mouse

Clone ID: clone JAMA-147

Antibody ID: AB_2661843

Vendor: Bio X Cell

Catalog Number: BE0256

Alternative Catalog Numbers: BE0256-50MG, BE0256-100MG, BE0256-1MG, BE0256-25MG, BE0256-5MG

Record Creation Time: 20260114T192948+0000

Record Last Update: 20260623T051047+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-mouse IL-1 R (CD121a).

No alerts have been found for InVivoMab anti-mouse IL-1 R (CD121a).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Xu X, et al. (2026) Commensal-derived trehalose monocorynomycolate triggers ?? T cell-driven protective ocular barrier immunity. *Immunity*, 59(2), 388.

Kim SH, et al. (2025) IL-10 sensing by lung interstitial macrophages prevents bacterial dysbiosis-driven pulmonary inflammation and maintains immune homeostasis. *Immunity*, 58(5), 1306.

Cho NW, et al. (2025) T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNF? *Inflammation. Cancer immunology research*, 13(2), 229.

Sharma D, et al. (2025) A myeloid Tet2-IL-1? axis modulates intestinal inflammation by restricting catecholaminergic stimulation of enterochromaffin cell differentiation. *Immunity*, 58(11), 2785.

Castaño D, et al. (2025) Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses. *Cell*, 188(26), 7461.

Hänggi K, et al. (2024) Interleukin-1? release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. *Cancer cell*, 42(12), 2015.

Lee J, et al. (2024) Impaired autophagy in myeloid cells aggravates psoriasis-like skin inflammation through the IL-1?/CXCL2/neutrophil axis. *Cell & bioscience*, 14(1), 57.

Kwon KW, et al. (2022) Host-directed anti-mycobacterial activity of colchicine, an anti-gout drug, via strengthened host innate resistance reinforced by the IL-1?/PGE2 axis. *British journal of pharmacology*, 179(15), 3951.

Xu W, et al. (2021) Early innate and adaptive immune perturbations determine long-term severity of chronic virus and *Mycobacterium tuberculosis* coinfection. *Immunity*, 54(3), 526.

Castro-Dopico T, et al. (2019) Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis. *Immunity*, 50(4), 1099.

Gimblet C, et al. (2017) Cutaneous Leishmaniasis Induces a Transmissible Dysbiotic Skin Microbiota that Promotes Skin Inflammation. *Cell host & microbe*, 22(1), 13.